Galera Therapeutics, Inc.
GRTX
$0.02
$0.00-6.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.92M | 8.06M | 9.78M | 11.00M | 11.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.16M | 8.47M | 11.54M | 14.15M | 17.71M |
| Operating Income | -6.16M | -8.47M | -11.54M | -14.15M | -17.71M |
| Income Before Tax | -8.99M | -13.38M | -16.37M | -19.16M | -19.82M |
| Income Tax Expenses | 0.00 | -203.00K | -203.00K | -203.00K | -203.00K |
| Earnings from Continuing Operations | -8.99 | -13.18 | -16.17 | -18.96 | -19.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.99M | -13.18M | -16.17M | -18.96M | -19.61M |
| EBIT | -6.16M | -8.47M | -11.54M | -14.15M | -17.71M |
| EBITDA | -6.14M | -8.45M | -11.52M | -14.13M | -17.47M |
| EPS Basic | -0.13 | -0.22 | -0.28 | -0.35 | -0.36 |
| Normalized Basic EPS | -0.04 | -0.07 | -0.11 | -0.15 | -0.20 |
| EPS Diluted | -0.13 | -0.22 | -0.28 | -0.35 | -0.36 |
| Normalized Diluted EPS | -0.04 | -0.07 | -0.11 | -0.15 | -0.20 |
| Average Basic Shares Outstanding | 350.87M | 306.76M | 262.64M | 218.53M | 217.56M |
| Average Diluted Shares Outstanding | 350.87M | 306.76M | 262.64M | 218.53M | 217.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |